Global Human Rotavirus Vaccine Market Growth 2025-2031
Description
The global Human Rotavirus Vaccine market size is predicted to grow from US$ 202 million in 2025 to US$ 248 million in 2031; it is expected to grow at a CAGR of 3.4% from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Rotavirus vaccine is used to protect against rotavirus infections which cause severe diarrhoea among young children. Symptoms of rotavirus infection include severe diarrhoea, vomiting, fever, and abdominal pain which can result in disease.
Rotavirus vaccine is administered by mouth and requires two or three doses starting around six weeks of age. The vaccine first became available in the United States in 2006.
LP Information, Inc. (LPI) ' newest research report, the “Human Rotavirus Vaccine Industry Forecast” looks at past sales and reviews total world Human Rotavirus Vaccine sales in 2024, providing a comprehensive analysis by region and market sector of projected Human Rotavirus Vaccine sales for 2025 through 2031. With Human Rotavirus Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Human Rotavirus Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Human Rotavirus Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Human Rotavirus Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Human Rotavirus Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Human Rotavirus Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Human Rotavirus Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Human Rotavirus Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Rotarix
RotaTeq
Rotavac
Rotavin-M1
Lanzhou lamb
Others
Segmentation by Application:
Hospitals & Clinics
Academic And Research
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Bharat Biotech
Merck
GlaxoSmithKline
Key Questions Addressed in this Report
What is the 10-year outlook for the global Human Rotavirus Vaccine market?
What factors are driving Human Rotavirus Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Human Rotavirus Vaccine market opportunities vary by end market size?
How does Human Rotavirus Vaccine break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Rotavirus vaccine is used to protect against rotavirus infections which cause severe diarrhoea among young children. Symptoms of rotavirus infection include severe diarrhoea, vomiting, fever, and abdominal pain which can result in disease.
Rotavirus vaccine is administered by mouth and requires two or three doses starting around six weeks of age. The vaccine first became available in the United States in 2006.
LP Information, Inc. (LPI) ' newest research report, the “Human Rotavirus Vaccine Industry Forecast” looks at past sales and reviews total world Human Rotavirus Vaccine sales in 2024, providing a comprehensive analysis by region and market sector of projected Human Rotavirus Vaccine sales for 2025 through 2031. With Human Rotavirus Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Human Rotavirus Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Human Rotavirus Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Human Rotavirus Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Human Rotavirus Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Human Rotavirus Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Human Rotavirus Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Human Rotavirus Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Rotarix
RotaTeq
Rotavac
Rotavin-M1
Lanzhou lamb
Others
Segmentation by Application:
Hospitals & Clinics
Academic And Research
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Bharat Biotech
Merck
GlaxoSmithKline
Key Questions Addressed in this Report
What is the 10-year outlook for the global Human Rotavirus Vaccine market?
What factors are driving Human Rotavirus Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Human Rotavirus Vaccine market opportunities vary by end market size?
How does Human Rotavirus Vaccine break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
78 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Human Rotavirus Vaccine by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Human Rotavirus Vaccine by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
